| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1971589 | Clinical Biochemistry | 2007 | 6 Pages |
Objectives:Evaluate a new whole blood (WB) HbA1c immunoassay and system with closed tube sampling (CTS) capability.Design and methods:Compare the Tina-quant Haemoglobin A1c Gen.2 (A1C-2) application on the COBAS INTEGRA 800 (I800) and new I800 dedicated system with CTS capability to current Integra applications and a HbA1c method accurate with common haemoglobin (Hb) variants.Results:CVs were ≤ 1.7%. Mean bias against National Glycohaemoglobin Standardization Program (NGSP) samples was 0.3 HbA1c %. Compared to the Hitachi Tina-quant® [a] HbA1c II (HbA1c II) assay (accurate with common Hb variants), mean bias was 0.04% and 0.21% HbA1c at 6% and 9%, respectively, with Hb AS variants; and − 0.01% and 0.26% HbA1c at 6% and 9%, respectively, with Hb AC variants.Conclusions:The Integra A1C-2 application is precise, accurate against NGSP-assigned samples and the Hb variants tested; and, the I800 dedicated system with CTS capability offers increased throughput and reduced sample handling.
